| Objective: IgA nephropathy (IgAN), one of the renal diseases, wasbelieved to be the most common pathologic types of primary glomerulardiseases. A lot of clinical studies showed recently there was a closelyrelationship between the prognosis of IgAN and the tubulointerstitiallesions. The aim of the present research was to investigate the mechanismof astragalus granules on preventing the tubulointerstitial involvement ofIgAN by establishing IgAN rats model and observing the effects ofastragalus granules on the tubulointerstitial involvement, and also theexpression of nuclear factor-kappa B (NF-κ3),monocyte chemoactivepeptide 1 (MCP-1), proteinuria,urine NAG excretion and renal pathology.Method: 28 SD rats were divided into three groups, the model, thetreatment and the control. IgAN model was got by taking orally bovine andtime-controlled injecting lipopolysaccharide (LPS) by way of tail vein andinjecting carbon tetrachloride(CCL4) intraperitoneally both in the modeland in the treatment as well. Astragalus granules was given to the treatmentgroup and normal SD rats serving as control. Pan-automatic biochemistryanalyzing meter was used to account the urine erythrocyte, to test the urineB-D-N-Acetyl glucosaminidase (NAG) and 24 hours proteinuria quantity.Immunofluorescence was performed to examine the immune complex IgAdeposition in frozen section of renal tissues. Immunohistochemistry was used to observe the effects of astragalus granules on the expression ofmonocyte chemoactive peptide 1(MCP-1) and nuclear factor-kappa B intubulointerstitial tissues of IgAN model rats, semi-quantitative method wasused to score the renal pathologic lesions.Results:(1) The number of the urine erythrocyte, demonstrated as mean±standard deviation is 74.02±16.58/ul in the treatment, and 24 hours'proteinuria quantity is 13.88±4.9 mg/L, the value of the urine NAG is2.84±0.31 U/L, they were all remarkably decreased comparing with that ofthe model group, they were 383.23±4.94/ul, 59.82±14.73 mg/L and5.24±0.8 U/L and a significant difference was found between the twogroups according to statistics, (P＜0.01).(2) The NFκBp65,MCP-1expression expressed by area were53.42±4.13% and 54.62±9.97% respectively in the model; they were27.57±3.35% and 25.57±3.79% in the treatment; as for the control, theywere 5.83±1.68% and 9.07±1.04%. Expression of the two in renal tissuesof the model group were all higher than those of the control and thetreatment, and there was notable differences between the three groupsstatistically, (P＜0.01).(3) The total pathological scores in the model group was 10.57±1.23,scores of the glomerule was 5.67±0.74, and the tubule, 5.0±0.81; while thetotal pathological scores in the treatment group was 6.03±0.46, and scores of the glomerule was 3.01±1.95, the value in the tubule was 3.01±0.49,scores in the treatment was lower than that of the model, with a notabledifference was found between the three groups statistically,(P＜0.01).Conclusions:(1) Astragalus can decrease the number of urine erythrocyte,proteinuria and urine NAG of IgAN model rats.(2) Astragalus can relieve the lesions in tubulointerstitum.(3) Mechanism of astragalus relieving tubulointerstitial lesions may beassociated with the role it play in down-regulating expression of NF-κB,MCP-1 in IgAN model rats.
|
PDF Full Text Request